Tatiana S. Satalkina

Tatiana S. Satalkina

Auto-generated profile, based on publicly available information

Tatiana S. Satalkina

Far Eastern Federal University

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2022 in "Arterial’naya Gipertenziya" ("Arterial Hypertension")
Verified
Journal Article
Open access
PDF file
TBT. A. Brodskaya
T. A. Brodskaya
BGB. I. Geltser
B. I. Geltser
TST. S. Satalkina
T. S. Satalkina
SKS. V. Knysh
S. V. Knysh
OSO. I. Shekunova
O. I. Shekunova
Артериальная гипертензия и рак молочной железы у женщин: механизмы коморбидности и лекарственной ятрогении

17 January 2023 in Pacific Medical Journal
Verified
Journal Article
Open access
PDF file
TST. S. Satalkina
T. S. Satalkina
TBT. A. Brodskaya
T. A. Brodskaya
BGB. I. Geltser
B. I. Geltser
Arterial hypertension (AH) is one of the most common cardiovascular complications of anticancer drug therapy. In this review article, we consider the main groups of anticancer drugs that may cause the development of iatrogenic AH, the pathophysiological mechanisms of increased blood pressure, as well as the clinical significance of AH developed during treatment with cytostatics and targeted drugs in the practice of an oncologist and a cardiologist. It was found that AH is frequently associated with the use of angiogenesis inhibitors, as well as alkylating cytostatics, antimetabolites, taxanes, and proteasome inhibitors. In addition, erythropoietins, glucocorticosteroids, and non-steroidal anti-inflammatory drugs used as part of supportive therapy may contribute to an increase in blood pressure. Management of hypertension in cancer patients is an important part of antitumor treatment therapy whose implementation contributes to improving their quality of life. Research into various clinical and pathophysiological aspects of cardiovascular disorders in cancer patients is becoming increasingly relevant, which is indicated by the rapid development of cardio-oncology, a new interdisciplinary field of knowledge aimed at developing practical recommendations for the prevention, diagnosis, and treatment of cardiovascular toxicity caused by anticancer therapy.

6 July 2023 in "Arterial’naya Gipertenziya" ("Arterial Hypertension")
Verified
Journal Article
Open access
PDF file
TST. S. Satalkina
T. S. Satalkina
BGB. I. Geltser
B. I. Geltser
TBT. A. Brodskaya
T. A. Brodskaya
ВКВ. Н. Котельников
В. Н. Котельников
Objective. The purpose of the study was to assess the daily profile of blood pressure (BP) and metabolic status in women with newly diagnosed breast cancer (BC) before starting chemotherapy (CHT).Design and methods. A prospective cohort study was conducted with the inclusion of 154 women aged 25 to 63 years with a median (Me) of 43,4 years with a newly diagnosed stage IIA–IIIB BC. The first group included 109 patients with normal or high normal “office” BP, the second group included 45 women with previously diagnosed stage 1 of hypertension with low and moderate cardiovascular risk according to the SCORE 2 scale. All examined patients underwent 24-hour BP monitoring (ABPM), anthropometric measurements: height, weight, waist (WC) and hip circumference (HC), calculation of body mass index, ratio WC/height × 100, WC/HC. Glucose, total cholesterol, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol, triglycerides, and cholesterol not associated with high-density lipoproteins were determined in fasting blood. Visceral adiposity index and lipid accumulation product were calculated.Results. According to the results of ABPM, two subgroups were distinguished among those examined with a normal level of clinical BP. The first included 55 women with normotension (50,5 %), the second — 54 (49,5 %) with newly diagnosed masked hypertension (MH). In those examined with hypertension (HTN) and MH, the level of systolic BP (SBP) and diastolic BP (DBP) both during the day and at night was significantly higher than in those with normotension (p < 0,0001). In those examined with MH, SBP and DBP indicators during the night exceeded similar parameters in the group of women with HTN, and during the waking period, differences were recorded only in the level of DBP, which was significantly higher in people with stable HTN. Variability, time index of SBP and DBP at night in women with MH were higher than in women with HTN. The indicator of the nocturnal decline among those examined with MH and HTN was less than 10 % (“non-dipper”). The morning rise in SBP among persons with stable HTN exceeded the level of this indicator in the MH group, and the values of the morning rise in DBP did not differ significantly. In case of BC comorbidity with HTN and MH, cardiometabolic risk factors (RF) were recorded more often: overweight, abdominal obesity, dyslipidemia. Correlation analysis showed direct relationships of varying severity between individual ABPM indicators and cardiometabolic RF.Conclusions. Among the examined subjects, a significant number of women appeared to have a combination of BC and HTN before the start of CHT. Our study showed that ABPM in women with newly diagnosed BC is a necessary tool for verifying MH before starting CHT. In turn, the presence of cardiometabolic RF increases the likelihood of comorbid BC and HTN. Taking into account the cardiotoxic effect of drug antitumor therapy for BC, the correction of RF and adequate treatment of HTN is recommended even before it is started.

14 March 2025 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
TST. S. Satalkina
T. S. Satalkina
TBT. A. Brodskaya
T. A. Brodskaya
BGB. I. Geltser
B. I. Geltser
ВКВ. Н. Котельников
В. Н. Котельников
Aim. To evaluate arterial stiffness and 24-hour blood pressure (BP) profile in breast cancer (BC) in women with normotension, masked hypertension (MH) and primary hypertension (HTN) before and after chemotherapy (CT) with a combination of doxorubicin and cyclophosphamide.Material and methods. The study involved 158 women with newly diagnosed stage IIA-IIIA BC. Before chemotherapy, the patients were divided into 2 groups. The first group included 109 women with normal clinical BP, and the second group included 49 women with previously diagnosed stage 1-2 HTN. Before chemotherapy and 7-14 days after its completion, 24-hour ambulatory BP monitoring (ABPM) and noninvasive arteriography were performed. The mean 24-hour systolic BP (SBP) and diastolic BP (DBP), variability, time indices of SBP and DBP, their nighttime decrease and morning rise were analyzed. The pulse wave velocity (PWV) in the aorta, augmentation index (AI), central systolic BP, pulse pressure, systolic and diastolic area indices and their ratio were determined.Results. According to ABPM conducted before the start of chemotherapy, two subgroups were identified among the examined patients with normal clinical BP. The first group included 55 (50,5%) women with normotension, while the second group — 54 (49,5%) women with newly diagnosed MH. The general trend of ABPM modification after chemotherapy was a decrease in mean 24-hour SBP and DBP, their excessive variability and a tendency towards tachycardia. Doxorubicin and cyclophosphamide-based chemotherapy is associated with an increase in PWV and AI in all groups of subjects, indicating an increase in arterial stiffness. These changes were more pronounced in the case of comorbidity of BC with MH and primary HTN.Conclusion. In BC women, a comprehensive assessment of the 24-hour BP profile and arterial stiffness, glomerular filtration rate and left ventricular myocardial ejection fraction is an informative tool for the timely detection of chemotherapy vascular toxicity and the prevention of adverse cardiovascular events.

19 September 2024 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
TBT. A. Brodskaya
T. A. Brodskaya
TST. S. Satalkina
T. S. Satalkina
BGB. I. Geltser
B. I. Geltser
ВКВ. Н. Котельников
В. Н. Котельников
Aim. To evaluate cardiometabolic risk (CMR) factors in women with breast cancer (BC) before and after chemotherapy (CT) with doxorubicin and cyclophosphamide.Material and methods. This prospective cohort study included 154 women with a median age of 43 years with newly diagnosed stage IIA-IIIB BC. Three following groups were identified among the examined women: with normal blood pressure (BP), masked hypertension (MH) and primary hypertension (HTN). All patients after BC surgery underwent 4 courses of chemotherapy with doxorubicin and cyclophosphamide lasting about 3 months. The assessment of CMR factors was carried out at 3 following stages: I — before chemotherapy; II and III — 7-14 days and 90-120 days after its completion. Fasting blood glucose, total cholesterol (TC), triglycerides (TGs), high-density (HDL-C) and low-density lipoprotein cholesterol (LDL-C), and non-HDL-C were determined. The atherogenicity coefficient, visceral obesity index (VAI) and lipid accumulation product (LAP) index were calculated.Results. In women with comorbidity of BC and HTN, the body mass index (BMI) decreased at stage II and returned to the initial level at stage III, while class I obesity was recorded in almost a third of patients. In the MH group, an increase in BMI was observed 90-120 days after the end of chemotherapy. In patients with normal BP, TC level did not change significantly during the follow-up, and among women with HTN, a significant increase in TC compared to the baseline was determined 90-120 days after the completion of chemotherapy. In patients with comorbidity of BC and HTN at stage III, the highest concentration of LDL-C, non-HDL-C and the lowest concentration of HDL-C in the blood were established, which distinguished them from individuals with normotension and MH. Hypertriglyceridemia was recorded in most patients with MH and hypertension after the completion of chemotherapy. The median values of TGs, VAI and LAP index in individuals with normal BP were significantly lower than in the comparison groups at all stages.Conclusion. In patients with BC after adjuvant chemotherapy with doxorubicin and cyclophosphamide, an increase in the level of atherogenic lipids and visceral obesity indicators is recorded, which is more pronounced in the case of comorbidity of BC and HTN. Metabolic status disorders after chemotherapy persisted for up to 3-4 months, which indicates the need for long-term monitoring of changes.

2 October 2026 in Volgograd Journal of Medical Research
Verified
Journal Article
Open access
PDF file
YPYulia Yu. Petukhova
Yulia Yu. Petukhova
ПЮПетухова Юлия Юрьевна
Петухова Юлия Юрьевна
TSTatiana S. Satalkina
Tatiana S. Satalkina
СССаталкина Татьяна Сергеевна
Саталкина Татьяна Сергеевна
KSKirill V. Stegniy
Kirill V. Stegniy
АИАпанасевич Владимир Иосифович
Апанасевич Владимир Иосифович
Bladder cancer is one of the most common malignant neoplasms, which are among the top ten in the structure of oncological pathology in many countries of the world. The increasing incidence of bladder cancer in the Russian Federation determines the need to use all the most effective medical technologies to reduce this socio-economic burden. A feature of the disease is the steadily recurrent nature of the course. Intravesical BCG therapy is one of the tools capable of controlling the frequency and timing of disease return. This area of antitumor pharmacotherapy becomes possible with the provision of the necessary equipment, compliance with the conditions for intravesical instillation with BCG vaccine, staff training, strict selection and preparation of patients. Purpose: Analysis of the experience in implementing intravesical BCG therapy in the treatment of non-muscle-invasive bladder cancer at a regional oncology clinic. Materials and methods: The study is based on an appeal to the regulations governing the procedure for BCG therapy in a regional oncological dispensary, in comparison with the current Clinical recommendations of the Russian Ministry of Health for the treatment of bladder cancer and the experience of other medical organizations. In accordance with the requirements of GOST R 57525-2017, a prospective clinical and economic follow-up was conducted with an analysis of the "cost of the disease" at the stage of intravesical BCG therapy. Results and discussion: The study reflects in detail the qualitative changes in the provision of medical care to patients with bladder cancer as a result of the introduction of intravesical immunotherapy. The clinical effectiveness of the organized line of activity is justified due to numerous scientific data confirming its effectiveness. According to the economic efficiency analysis, the financial feasibility of BCG therapy, in particular with the use of a domestically produced vaccine, is obvious. The results of the analysis are confirmed by the published research experience of specialists in the field of oncourology. Conclusion: The introduction of intravesical BCG therapy significantly improves the quality of specialized medical care for patients with bladder cancer, is clinically effective and economically justified. A valuable aspect of the organization of this area of medical care is the absence of the need for significant financial investments in the current activities of the institution. The practical application of the BCG vaccine in the care of oncourological patients complies with the Clinical recommendations of the Russian Ministry of Health and modern international standards for the treatment of bladder cancer.